|
Oct 10
|
Will Biogen (BIIB) Beat Estimates Again in Its Next Earnings Report?
|
|
Oct 10
|
Biogen scores breakthrough status for anti-rejection transplant medication
|
|
Oct 9
|
Biogen Receives U.S. FDA Breakthrough Therapy Designation for Felzartamab for the Treatment of Antibody-Mediated Rejection in Kidney Transplant Recipients
|
|
Oct 8
|
New Higher Dose Nusinersen Efficacy and Safety Data Presented at World Muscle Society Congress, Highlight Potential to Maximize Benefit of Nusinersen in SMA
|
|
Oct 2
|
Biogen Inc. (BIIB): Among the Best Bargain Stocks to Buy In October
|
|
Sep 27
|
SAGE, BIIB End Collaboration for Neurology Candidate SAGE-324
|
|
Sep 26
|
Biogen Terminates Collaboration With Sage Therapeutics For Neurological Disorder Candidate
|
|
Sep 25
|
Biogen's Lupus Candidate Meets Key Goals in Phase III Study
|
|
Sep 24
|
Biogen stock opened higher on positive lupus readout
|
|
Sep 24
|
Biogen/UCB Partnered Autoimmune Disease Candidate Hits Primary Goal In Late-Stage Study, Sets Stage Another Pivotal Trial
|
|
Sep 24
|
UCB and Biogen lupus drug succeeds in Phase III, but data yet to be released
|
|
Sep 24
|
UCB and Biogen Announce Positive Topline Results From Phase 3 Study of Dapirolizumab Pegol in Systemic Lupus Erythematosus and are Initiating Second Phase 3 Study in 2024
|
|
Aug 20
|
Do Options Traders Know Something About Biogen (BIIB) Stock We Don't?
|
|
Aug 15
|
Will Ionis' (IONS) Wholly-Owned Drugs Drive Future Growth?
|
|
Jul 30
|
Watch These 5 Biotech Stocks for Q2 Earnings: Beat or Miss?
|
|
Jul 30
|
Acadia Pharmaceuticals (ACAD) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
|
|
Jul 30
|
Countdown to Biogen (BIIB) Q2 Earnings: A Look at Estimates Beyond Revenue and EPS
|
|
Jul 30
|
Biogen, Beckman Coulter and Fujirebio to Collaborate on Blood-Based Biomarkers and Test for Tau Pathology in Alzheimer’s Disease
|
|
Jul 29
|
EU CHMP snubs Biogen and Eisai’s Alzheimer’s therapy Leqembi
|
|
Jul 29
|
Alzheimer’s Disease: Some trials to watch over the next year
|